RARS1 and neoplasm: The combination of anti‐tumour strategies targeting RARs/RXRs with TNFAIP3 presents a novel avenue for managing ESCC, wherein ZSH‐2208 plays a pivotal role due to its inherent anti‐tumour activity and its potential to facilitate the development of innovative RA analogues in the anti‐tumour domain.